The Fahed Lab is focused on genome-informed clinical trials. Dr. Fahed is Principal Investigator of the  NHLBI-funded PROACT clinical trials, testing a polygenic risk-based detection strategy for subclinical coronary atherosclerosis to improve cardiovascular health and treat coronary plaque. Additionally, we participate in multisite clinical trials and registries for innovative catheter-based coronary interventions, advanced phenotyping and drugs for coronary artery disease. Dr. Fahed has been site principal investigator, co-investigator, or sub-investigator in numerous clinical studies:

• Heart Attack Research Protocol (HARP)
• Homozygous Familial Hypercholesterolemia International Clinical Collaboration (HICC)
• ELIPSE HoFH: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
• The PROTECT IV Trial: Impella®-Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function
• TARGET IV NA : A prospective multicenter Randomized Assessment of the FirehawkTM rapamycin TARGET eluting cobalt chromium coronary stent system – North American Trial
• The HeartFlow REVEAL PLAQUE Study: A Prospective Multicenter Study to Analyze Plaque using CCTA
• ECLIPSE: Evaluation of Treatment Strategies for Severe Calcific Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug Eluting Stents
• COSIRA-II: Efficacy of the Coronary Sinus Reducer in Patients with Refractory Angina II
• AGENT IDE:  Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis
• Ringer IDE Study: A Prospective, Multicenter, Single-arm Investigation of the Ringer Perfusion Balloon Catheter Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE-STEMI for Seniors)
• Short-Cut Trial: Shockwave Lithoplasty Compared To Cutting Balloon Treatment in Calcified Coronary Disease
• Study to determine the clinical significance of intravascular OCT-NIRAF
• Coronary Microvascular Disease Registry (CMDR)